PSNL
Personalis, Inc. NASDAQ Listed Jun 20, 2019$5.99
Mkt Cap $531.9M
52w Low $3.84
28.1% of range
52w High $11.50
50d MA $6.91
200d MA $7.49
P/E (TTM)
-6.3x
EV/EBITDA
-8.7x
P/B
2.0x
Debt/Equity
0.1x
ROE
-31.1%
P/FCF
-8.9x
RSI (14)
—
ATR (14)
—
Beta
2.21
50d MA
$6.91
200d MA
$7.49
Avg Volume
1.5M
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
1330 O’Brien Drive · Fremont, CA 94025 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -0.23 | -0.29 | -26.1% | 5.99 | -4.8% | -0.2% | — | — | — | — | — |
| Feb 26, 2026 | AMC | -0.31 | -0.26 | +16.1% | 9.03 | -4.7% | +0.3% | +0.0% | -4.3% | +3.0% | -4.1% | — |
| Nov 4, 2025 | AMC | -0.28 | -0.24 | +14.3% | 8.73 | -8.9% | -12.3% | -6.1% | -3.6% | +24.5% | -2.2% | — |
| Aug 5, 2025 | AMC | -0.25 | -0.23 | +8.0% | 5.64 | -26.1% | -21.8% | +3.2% | -0.9% | -0.2% | +1.6% | — |
| May 6, 2025 | AMC | -0.23 | -0.18 | +21.7% | 4.00 | +9.8% | +21.0% | +6.6% | -2.3% | +1.2% | +0.8% | — |
| Feb 27, 2025 | AMC | -0.32 | -0.23 | +28.1% | 4.24 | -5.4% | -2.4% | -0.7% | +0.0% | +9.2% | -6.0% | — |
| Nov 6, 2024 | AMC | -0.33 | -0.64 | -93.9% | 5.58 | -14.0% | -22.6% | +5.3% | +8.1% | +6.3% | -9.2% | — |
| Aug 7, 2024 | AMC | -0.34 | -0.24 | +29.4% | 2.88 | +19.8% | +19.1% | -5.0% | +32.2% | +8.1% | -4.3% | — |
| May 8, 2024 | AMC | -0.44 | -0.26 | +40.9% | 1.57 | +8.9% | +5.1% | -4.8% | -1.9% | -1.3% | -5.9% | — |
| Feb 28, 2024 | AMC | -0.53 | -0.46 | +13.2% | 1.46 | -9.6% | +6.2% | +9.0% | +3.0% | -2.3% | +2.9% | — |
| Nov 7, 2023 | AMC | -0.54 | -0.51 | +5.6% | 0.96 | +15.3% | +21.5% | -19.7% | +8.5% | +4.9% | +10.3% | — |
| Aug 8, 2023 | AMC | -0.56 | -0.50 | +10.7% | 1.98 | -4.0% | +0.5% | -1.5% | +4.6% | -7.8% | -4.2% | — |
| May 3, 2023 | AMC | -0.62 | -0.61 | +1.6% | 2.42 | -7.0% | -5.0% | -2.6% | +1.3% | -1.8% | -4.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $8.93 | $8.55 | -4.3% | -4.1% | -8.4% | +4.1% | +1.8% | -4.3% |
| Feb 27 | Needham | Maintains | Buy → Buy | — | $9.03 | $8.61 | -4.7% | +0.3% | +0.0% | -4.3% | +3.0% | -4.1% |
| Feb 11 | BTIG | Maintains | Buy → Buy | — | $8.62 | $8.54 | -0.9% | +3.2% | -5.7% | -2.1% | +4.4% | +5.0% |
| Jan 26 | Guggenheim | Maintains | Buy → Buy | — | $10.17 | $10.28 | +1.1% | +1.9% | -0.4% | -3.2% | -0.2% | -6.0% |
| Jan 9 | BTIG | Maintains | Buy → Buy | — | $8.38 | $8.53 | +1.8% | -3.3% | +5.8% | +2.5% | +5.9% | +3.3% |
| Dec 2 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $9.68 | $9.76 | +0.8% | +4.3% | +0.7% | +3.0% | -8.8% | +2.7% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.63 | $8.63 | +0.0% | -2.2% | -5.1% | -5.1% | -1.2% | -0.4% |
| Nov 11 | BTIG | Maintains | Buy → Buy | — | $8.63 | $8.63 | +0.0% | -2.2% | -5.1% | -5.1% | -1.2% | -0.4% |
| Nov 11 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $8.63 | $8.63 | +0.0% | -2.2% | -5.1% | -5.1% | -1.2% | -0.4% |
| Nov 11 | Guggenheim | Maintains | Buy → Buy | — | $8.63 | $8.63 | +0.0% | -2.2% | -5.1% | -5.1% | -1.2% | -0.4% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.66 | $7.66 | +0.0% | -6.1% | -3.6% | +24.5% | -2.2% | -5.1% |
| Nov 5 | Needham | Maintains | Buy → Buy | — | $8.73 | $7.95 | -8.9% | -12.3% | -6.1% | -3.6% | +24.5% | -2.2% |
| Oct 22 | BTIG | Maintains | Buy → Buy | — | $9.57 | $9.47 | -1.0% | -6.7% | +5.8% | +2.4% | +0.0% | +0.7% |
| Sep 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.24 | $5.28 | +0.8% | +1.5% | +1.3% | +0.0% | +13.2% | -4.1% |
| Aug 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.64 | $4.17 | -26.1% | -21.8% | +3.2% | -0.9% | -0.2% | +1.6% |
| May 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.00 | $4.39 | +9.8% | +21.0% | +6.6% | -2.3% | +1.2% | +0.8% |
| Apr 10 | Needham | Maintains | Buy → Buy | — | $3.38 | $3.28 | -3.0% | -10.4% | +8.3% | -1.2% | +0.6% | +0.9% |
| Feb 28 | Needham | Maintains | Buy → Buy | — | $4.24 | $4.01 | -5.4% | -2.4% | -0.7% | +0.0% | +9.2% | -6.0% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.24 | $4.01 | -5.4% | -2.4% | -0.7% | +0.0% | +9.2% | -6.0% |
| Jan 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.12 | $5.90 | -3.6% | -5.1% | -6.4% | -7.9% | +7.0% | -2.6% |
| Jan 8 | Lake Street | Maintains | Buy → Buy | — | $5.98 | $6.02 | +0.7% | -6.4% | -0.2% | -4.3% | -4.1% | +0.8% |
| Jan 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.98 | $6.02 | +0.7% | -6.4% | -0.2% | -4.3% | -4.1% | +0.8% |
| Jan 8 | Needham | Maintains | Buy → Buy | — | $5.98 | $6.02 | +0.7% | -6.4% | -0.2% | -4.3% | -4.1% | +0.8% |
| Dec 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.26 | $5.69 | +8.2% | +9.3% | +3.5% | +2.4% | +2.8% | -6.2% |
| Dec 20 | Needham | Maintains | Buy → Buy | — | $5.26 | $5.69 | +8.2% | +9.3% | +3.5% | +2.4% | +2.8% | -6.2% |
| Nov 7 | Needham | Maintains | Buy → Buy | — | $5.58 | $4.80 | -14.0% | -22.6% | +5.3% | +8.1% | +6.3% | -9.2% |
| Aug 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.99 | $6.01 | +0.3% | -2.5% | -2.6% | +11.4% | -9.9% | +4.6% |
| Aug 16 | BTIG | Maintains | Buy → Buy | — | $5.07 | $5.16 | +1.8% | +18.1% | -2.5% | -2.6% | +11.4% | -9.9% |
| Aug 16 | Needham | Maintains | Buy → Buy | — | $5.07 | $5.16 | +1.8% | +18.1% | -2.5% | -2.6% | +11.4% | -9.9% |
| Jun 21 | Needham | Maintains | Buy → Buy | — | $1.23 | $1.22 | -0.8% | -0.8% | +0.8% | -1.6% | -1.7% | +1.7% |
| May 9 | Needham | Maintains | Buy → Buy | — | $1.57 | $1.71 | +8.9% | +5.1% | -4.8% | -1.9% | -1.3% | -5.9% |
| Apr 11 | Needham | Maintains | Buy → Buy | — | $1.38 | $1.38 | +0.0% | -0.7% | -7.3% | -0.8% | -1.6% | -3.2% |
| Feb 29 | Needham | Maintains | Buy → Buy | — | $1.46 | $1.32 | -9.6% | +6.2% | +9.0% | +3.0% | -2.3% | +2.9% |
| Jan 5 | Needham | Maintains | Buy → Buy | — | $2.00 | $2.08 | +4.0% | +7.0% | +2.3% | -2.7% | -6.6% | -9.0% |
| Nov 8 | Needham | Maintains | Buy → Buy | — | $0.96 | $1.11 | +15.3% | +21.5% | -19.7% | +8.5% | +4.9% | +10.3% |
| Aug 9 | Needham | Maintains | Buy → Buy | — | $1.98 | $1.90 | -4.0% | +0.5% | -1.5% | +4.6% | -7.8% | -4.2% |
| Aug 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.98 | $1.90 | -4.0% | +0.5% | -1.5% | +4.6% | -7.8% | -4.2% |
| May 4 | Needham | Maintains | Buy → Buy | — | $2.42 | $2.25 | -7.0% | -5.0% | -2.6% | +1.3% | -1.8% | -4.5% |
| May 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.42 | $2.25 | -7.0% | -5.0% | -2.6% | +1.3% | -1.8% | -4.5% |
| Feb 27 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $2.95 | $3.01 | +2.0% | +2.4% | -0.3% | -13.0% | +0.0% | +7.3% |
| Feb 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.18 | $2.94 | -7.5% | -7.2% | +2.4% | -0.3% | -13.0% | +0.0% |
| Feb 24 | Needham | Maintains | Buy → Buy | — | $3.18 | $2.94 | -7.5% | -7.2% | +2.4% | -0.3% | -13.0% | +0.0% |
| Feb 6 | Needham | Upgrade | Hold → Buy | — | $3.90 | $3.63 | -6.9% | -0.5% | +7.5% | -9.6% | -4.5% | -1.9% |
| Nov 4 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $2.70 | $2.73 | +1.1% | -6.3% | -8.3% | +0.4% | -2.6% | +12.8% |
| Nov 3 | Citigroup | Maintains | Buy → Buy | — | $2.70 | $2.52 | -6.7% | +0.0% | -6.3% | -8.3% | +0.4% | -2.6% |
| Nov 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.70 | $2.52 | -6.7% | +0.0% | -6.3% | -8.3% | +0.4% | -2.6% |
| Aug 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.48 | $4.57 | +2.0% | +0.4% | +10.2% | -8.9% | -10.6% | +18.1% |
| May 6 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $5.38 | $5.30 | -1.5% | -3.3% | -16.2% | +0.9% | -8.2% | +13.1% |
| May 5 | Citigroup | Maintains | Buy → Buy | — | $5.97 | $5.75 | -3.7% | -9.9% | -3.3% | -16.2% | +0.9% | -8.2% |
| May 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.97 | $5.75 | -3.7% | -9.9% | -3.3% | -16.2% | +0.9% | -8.2% |
No insider trades available.
8-K
Unknown — 8-K Filing
Dr. Chen received restricted stock upon his appointment, aligning his long-term compensation with shareholder interests and signaling the company views this leadership role as strategically important.
Mar 17
8-K
Personalis, Inc. -- 8-K Filing
Personalis secured milestone Medicare coverage approvals for breast and lung cancer surveillance in Q4 2025, potentially expanding reimbursement and revenue opportunities for its precision oncology genomics platform.
Feb 26
Data updated apr 26, 2026 9:02pm
· Source: massive.com